A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)

NCT05885412 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)

Interventions

GENETIC: RP-A601

Sponsor

Rocket Pharmaceuticals Inc.